IXHL News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$36.1M

Volume

27.61K

Next Earnings

November 13th

Chart Earnings News About Insider Filings

Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsightOver 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea.GlobeNewswire Inc. · Oct 13, 2026

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42XIncannex Healthcare announced first patient dosing in the DReAMzz Phase 2 dose-optimization study of IHL-42X, its oral fixed-dose combination candidate for treating obstructive sleep apnea. The milestone follows positive Phase 2 RePOSA results showing AHI reductions up to 83% and FDA Fast Track designation. The DReAMzz study aims to optimize dose selection and strengthen the clinical foundation for planned Phase 3 development.GlobeNewswire Inc. · Aug 25, 2026

Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial FlexibilityIncannex Healthcare received A$6.0 million in R&D tax incentive refunds from the Australian Government with an additional A$5.1 million expected later in 2026, totaling over A$11.1 million in non-dilutive capital. The company plans to use these proceeds to advance clinical programs including IHL-42X and PSX-001, while maintaining its share repurchase program and strengthening its debt-free balance sheet.GlobeNewswire Inc. · Jun 10, 2026

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech BreakthroughIncannex Healthcare Inc. (Nasdaq: IXHL) has been recognized as the winner of the 'Best New Technology Solution for Drug Development' at the 10th annual MedTech Breakthrough Awards for its lead drug candidate IHL-42X, an oral fixed-dose combination therapy for obstructive sleep apnea. The Phase 2 RePOSA trial demonstrated statistically significant improvements in key endpoints including reductions in apnea-hypopnea index, improved oxygenation, sleep quality, and daytime fatigue.GlobeNewswire Inc. · May 7, 2026

Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 OutcomesIncannex Healthcare announced an enhanced clinical development strategy for IHL-42X, its lead oral drug candidate for obstructive sleep apnea (OSA), following statistically significant Phase 2 results. The company received FDA Fast Track Designation and plans to conduct a Phase 2 crossover dose-optimization study (DReAMzz) to optimize the drug's efficacy before advancing to a streamlined Phase 3 program. Phase 2 data showed significant improvements in both objective physiological measures and patient-reported outcomes with no serious adverse events.GlobeNewswire Inc. · Mar 12, 2026

Incannex Healthcare Announces Additional Appointments to Clinical Advisory BoardIncannex Healthcare Inc. (Nasdaq: IXHL) announced the appointment of three distinguished members to its Clinical Advisory Board: Murray B. Stein, MD, MPH from UCSD; Andrew Cutler, MD from SUNY Upstate Medical University; and Amir Kalali, MD. The CAB will provide clinical and scientific guidance as PSX-001, an oral synthetic psilocybin treatment for generalized anxiety disorder, advances through clinical and regulatory development.GlobeNewswire Inc. · Jan 29, 2026

4 Psychedelic Stocks to Consider as Clinical Trials Heat upSeveral biotechnology firms have psychedelic treatments in development, with promising results from clinical trials. The psychedelic market is expected to grow significantly, and most investors are favorable towards psychedelic stocks.Investing.com · Aug 6, 2024

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep ApneaNEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that patient dosing has commenced in the Company’s Phase 2/3 clinical trial to assess safety and efficacy of IHL-42X in patients with obstructive sleep apnea (‘OSA’).GlobeNewswire Inc. · May 30, 2024

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorderMELBOURNE, Australia and NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-O for treatment of Opioid Use Disorder (OUD).GlobeNewswire Inc. · May 7, 2024

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionShares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results. Bumble reported quarterly losses of 19 cents per share which missed the analyst consensus estimate of 12 cents per share. The company reported quarterly sales of $273.64 million which missed the analyst consensus estimate of $275.29 million. Bumble shares dipped 11.6% to $11.65 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Vivani Medical, Inc. (NASDAQ: VANI) shares jumped 289% to $3.93 after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139. Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) climbed 190% to $2.4598. Adial Pharmaceuticals secured new US patent covering lead product for alcohol use disorder. vTv Therapeutics Inc. (NASDAQ: VTVT) gained 112% to $17.65 after the company announced a $51 million private placement from healthcare-focused institutional investors and the JDRF T1D Fund. Bit Brother Limited (NASDAQ: BETS) shares rose 63.7% to $4.0750. Beyond Meat, Inc. (NASDAQ: BYND) climbed 45% to $10.90 as the company reported stronger-than-expected sales for its fourth quarter. Incannex Healthcare Inc. (NASDAQ: IXHL) gained 43.6% to $6.06 after the company announced its Psi-GAD1 trial met its primary endpoint. Bandwidth Inc. (NASDAQ: BAND) surged 43.3% to $17.41 after the company reported better-than-expected fourth quarter financial results and issued FY24 revenue guidance above estimates. Imunon, Inc. (NASDAQ: IMNN) climbed 38% to $0.98. Applied Therapeutics, Inc. (NASDAQ: APLT) surged 36% to $7.59 after the company announced FDA acceptance and priority review of the NDA for govorestat for the treatment of Classic Galactosemia. The company also announced a $100 million private placement. Movella Holdings Inc. (NASDAQ: MVLA) gained 33.5% to $0.33. LifeStance Health Group, Inc. (NASDAQ: LFST) gained 31.5% to $8.81 following strong quarterly sales. AirNet Technology Inc. (NASDAQ: ANTE) rose 31.3% to $1.05. AirNet announced changes in senior management team. Polestar Automotive Holding UK PLC (NASDAQ: PSNY) rose 29.9% to $1.9350. Polestar secured $1 billion external funding. Editas Medicine, Inc. (NASDAQ: EDIT) gained 27.7% to $11.31 after the company reported better-than-expected fourth-quarter financial results. TG Therapeutics, ...Benzinga · Feb 28, 2024

IXHLIncannex Healthcare Limited Common Stock

IXHL

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any IXHL yet.

Related Tickers

Earnings

Mkt Cap

$35.4M

Volume

27.61K

Next Earnings

November 13th